{'fraction_non_alphanumeric': 0.0315031503150315, 'fraction_numerical': 0.016201620162016202, 'mean_word_length': 5.427745664739884, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interleukin-17A a potential therapeutic target in chronic lung diseases.

BACKGROUND
Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has gained a lot of attention because of its involvement in respiratory diseases. Interleukin-17 cytokine family includes six members, out of which IL-17A participates towards the immune responses in allergy and inflammation. It also modulates the progression of respiratory disorders.


OBJECTIVE
The present review is an insight into the involvement and contributions of the pro-inflammatory cytokine IL-17A in chronic respiratory diseases like idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary distress (COPD), asthma, pneumonia, obliterative bronchiolitis, lung cancer and many others.


CONCLUSION
IL-17A is a major regulator of inflammatory responses. In all the mentioned diseases, IL-17A plays a prime role in inducing the diseases, whereas the lack of this pro-inflammatory cytokine reduces the severity of respective respiratory diseases. Thereby, this review suggests IL-17A as an instrumental target in the chronic respiratory diseases.